Mohammad Rafati Navaei

Dr. Mohammad Rafati Navaei

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Interdisciplinary CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
AAAhmad Ali Amirghofran
Ahmad Ali Amirghofran
SMSeyed Alireza Mirhosseini
Seyed Alireza Mirhosseini
RNRoozbeh Narimani-Javid
Roozbeh Narimani-Javid
MEMohammad Reza Edraki
Mohammad Reza Edraki
MNMohammad Rafati Navaei
Mohammad Rafati Navaei
AAAlireza Arzhangzadeh
Alireza Arzhangzadeh
Objectives: When tricuspid valve repair is unfeasible due to extensive damage or a complex congenital malformation, surgeons consider tricuspid valve replacement (TVR). However, it is still controversial and challenging to choose the best substitute. We aimed to introduce the innovative intraoperatively valve construction using the native right atrial appendage (RAA) tissue for TVR and investigate the short-term outcomes. Methods: This study recruited paediatric and adult patients with unrepairable severe tricuspid regurgitation (TR) who needed TVR. The patient’s RAA tissue was harvested and used to reconstruct a native bileaflet valve during surgery. Transthoracic echocardiography was conducted before operation, 6, and 12 months after surgery. Results: The procedure was successfully executed on 3 patients with valve destruction as a result of infective endocarditis, and 3 patients who had severe TR due to congenital anomalies. There was no mortality or related morbidity. All the constructed valves had proper function with no complications after the surgery. Follow-up echocardiographic studies showed stable and satisfactory valve function with no regurgitation or significant stenosis. Conclusions: The novel tricuspid valve operation using native RAA tissue demonstrates promising short-term results. Further studies with larger cohorts and longer follow-ups are required to confirm the technique’s reliability and long-term effectiveness.

26 August 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MMMohammad-Taghi Majnoon
Mohammad-Taghi Majnoon
MSMohadese Shahidzade
Mohadese Shahidzade
MRMohammad Mehdi Rajabi
Mohammad Mehdi Rajabi
MVMohammad Vasei
Mohammad Vasei
BGBehdad Gharib
Behdad Gharib
MNMohammad Rafati Navaei
Mohammad Rafati Navaei
Primary cardiac tumors are very rare in infants. Most of them are benign, such as rhabdomyoma. Malignant tumors like leiomyosarcoma are extremely uncommon

16 July 2026 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
AAAhmad Ali Amirghofran
Ahmad Ali Amirghofran
AAAlireza Arzhangzadeh
Alireza Arzhangzadeh
SKSoorena Khorshidi
Soorena Khorshidi
SNSalma Nozhat
Salma Nozhat
JKJavad Kojuri
Javad Kojuri
MNMohammad Rafati Navaei
Mohammad Rafati Navaei
Background: Redo coronary artery bypass grafting (Redo-CABG) poses significant challenges due to complex coronary anatomy and limited conduit availability. In patients with a previously patent left internal mammary artery (LIMA), reusing it as an inflow source for total arterial revascularization (TAR) may offer a durable, stroke-sparing strategy. This study evaluated the safety and midterm outcomes of reusing a patent LIMA as an inflow source in Redo-CABG. Methods: This retrospective case series included 24 patients who underwent Redo-CABG at Faghihi and Dena Hospitals (Shiraz University of Medical Sciences) between March 2015 and October 2023. Consecutive patients were included to minimize selection bias. All patients had a patent LIMA confirmed by angiography or computed tomography angiography (CTA). Arterial grafts (right internal mammary and/or radial artery) were anastomosed to the patent LIMA to achieve complete TAR. Outcomes included perioperative complications, graft patency on CTA, and midterm major adverse cardiac or cerebrovascular events (MACCE). Results: All patients achieved complete TAR with no hospital or 30-day mortality. One patient required reoperation for bleeding. Mean postoperative ejection fraction was 44.5 ± 4.6%, and mean ICU stay was 3.1 ± 0.9 days. Early postoperative CT angiography (at 3 months) and midterm follow-up imaging (median 3.5 years; completed in a subgroup of 12 patients) demonstrated complete graft patency in all evaluated conduits, with no recorded MACCE. Conclusions: Reusing a patent LIMA as an inflow source for total arterial grafting in Redo-CABG appears to be a feasible and safe alternative for high-risk patients with limited conduit options. This approach minimizes extensive aortic manipulation, potentially offering a theoretical advantage in minimizing neurological risks. However, the retrospective, single-center design and small sample size preclude definitive conclusions regarding superiority, warranting further comparative evaluation in larger multicenter studies.